Entering text into the input field will update the search result below

InMed begins B2B sales of cannabinoid THCV

Jun. 09, 2022 8:56 AM ETInMed Pharmaceuticals Inc. (INM) Stock, IN:CA StockBy: Ravikash Bakolia, SA News Editor

marijuana leaf

Irina Gutyryak/iStock via Getty Images

  • InMed Pharmaceuticals (NASDAQ:INM) (OTCQX:IMLFF) said it launched B2B (business-to-business) sales of rare cannabinoid delta 9-dominant tetrahydrocannabivarin (d9-THCV) in the health and wellness sector via its subsidiary BayMedica.
  • "In anticipation of this launch, we have expanded internal sales and marketing infrastructure, developed new distribution channels and optimized the supply chain to ensure a consistent and reliable supply of a high quality product," said Shane Johnson, MD, SVP and General Manager of BayMedica.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
INM
--
IN:CA
--